On this page
Nystatin
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Polyene Antifungal [EPC] | EPC | All 12 members |
| Polyenes [CS] | CS | All 13 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 208581-001 | NYSTATIN | POWDER | NYSTATIN | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | June 8, 2017 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250930). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species . Nystatin topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Very moist lesions are best treated with the topical dusting powder. Adults and Pediatric Patients (Neonates and Older): Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Nystatin topical powder is contraindicated in patients with a history of hypersensitivity to any of its components.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The frequency of adverse events reported in patients using nystatin topical preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS: General .)
Description
openFDA Drug LabelingDESCRIPTION Nystatin is a polyene antifungal antibiotic obtained from Streptomyces nursei. The molecular formula for Nystatin is C 47 H 75 NO 17 . The molecular weight of Nystatin is 926.1. Structural formula: Nystatin Topical Powder USP is for dermatologic use. Nystatin Topical Powder USP contains 100,000 USP nystatin units per gram dispersed in talc. Structural Formula
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Nystatin topical powder is supplied as 100,000 units nystatin per gram in plastic squeeze bottles: 15g (NDC 69315-306-15) 30g (NDC 69315-306-30) 60g (NDC 69315-306-60) STORAGE Store at 20°C to 25°C (68°F to 77°F)[see USP Controlled Room Temperature]; avoid excessive heat (40°C/104°F). Keep tightly closed. Manufactured for: Leading Pharma LLC, Fairfield, NJ 07004 Manufactured by: Lyne Laboratories, Inc. Brockton, MA 02301 R1-01/20
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: NYSTATIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 65415-1371-2 | 65415-1371 | Antibiotice SA | 16 kg in 1 CARTON (65415-1371-2) | March 20, 2014 |
| 65415-1372-3 | 65415-1372 | Antibiotice SA | 8 kg in 1 CARTON (65415-1372-3) | March 20, 2014 |
| 68254-2506-1 | 68254-2506 | Concord Biotech Limited | 1 BAG in 1 DRUM (68254-2506-1) / 5 kg in 1 BAG | October 8, 2024 |
| 75907-060-30 | 75907-060 | Dr. Reddy's Labratories Inc. | 30 g in 1 BOTTLE, PLASTIC (75907-060-30) | May 28, 2024 |
| 75907-060-44 | 75907-060 | Dr. Reddy's Labratories Inc. | 15 g in 1 BOTTLE, PLASTIC (75907-060-44) | May 28, 2024 |
| 75907-060-60 | 75907-060 | Dr. Reddy's Labratories Inc. | 60 g in 1 BOTTLE, PLASTIC (75907-060-60) | May 28, 2024 |
| 67630-0016-2 | 67630-0016 | FUJIAN FUKANG PHARMACEUTICAL CO., LTD. | 10 kg in 1 DRUM (67630-0016-2) | February 13, 2026 |
| 67630-0016-6 | 67630-0016 | FUJIAN FUKANG PHARMACEUTICAL CO., LTD. | 20 kg in 1 DRUM (67630-0016-6) | February 13, 2026 |
| 62991-2785-1 | 62991-2785 | LETCO MEDICAL, LLC | 100000000 [iU] in 1 JAR (62991-2785-1) | June 19, 2009 |
| 62991-2785-2 | 62991-2785 | LETCO MEDICAL, LLC | 500000000 [iU] in 1 JAR (62991-2785-2) | June 19, 2009 |
| 62991-2785-3 | 62991-2785 | LETCO MEDICAL, LLC | 1000000000 [iU] in 1 JAR (62991-2785-3) | June 19, 2009 |
| 62991-2785-4 | 62991-2785 | LETCO MEDICAL, LLC | 2000000000 [iU] in 1 JAR (62991-2785-4) | June 19, 2009 |
| 62991-2785-5 | 62991-2785 | LETCO MEDICAL, LLC | 5000000000 [iU] in 1 JAR (62991-2785-5) | June 19, 2009 |
| 62991-2785-6 | 62991-2785 | LETCO MEDICAL, LLC | 1500000000 [iU] in 1 PAIL (62991-2785-6) | June 19, 2009 |
| 69315-306-15 | 69315-306 | Leading Pharma, LLC | 15 g in 1 BOTTLE, PLASTIC (69315-306-15) | April 23, 2018 |
| 69315-306-30 | 69315-306 | Leading Pharma, LLC | 30 g in 1 BOTTLE, PLASTIC (69315-306-30) | April 23, 2018 |
| 69315-306-60 | 69315-306 | Leading Pharma, LLC | 60 g in 1 BOTTLE, PLASTIC (69315-306-60) | April 23, 2018 |
| 38779-0242-0 | 38779-0242 | Medisca Inc. | 1538.5 g in 1 PAIL (38779-0242-0) | July 16, 2015 |
| 38779-0242-1 | 38779-0242 | Medisca Inc. | 7.7 g in 1 JAR (38779-0242-1) | July 16, 2015 |
| 38779-0242-2 | 38779-0242 | Medisca Inc. | 23.1 g in 1 JAR (38779-0242-2) | July 16, 2015 |
| 38779-0242-3 | 38779-0242 | Medisca Inc. | 15.5 g in 1 JAR (38779-0242-3) | July 16, 2015 |
| 38779-0242-5 | 38779-0242 | Medisca Inc. | 76.9 g in 1 JAR (38779-0242-5) | July 16, 2015 |
| 38779-0242-6 | 38779-0242 | Medisca Inc. | 153.8 g in 1 JAR (38779-0242-6) | July 16, 2015 |
| 38779-0242-8 | 38779-0242 | Medisca Inc. | 307.7 g in 1 JAR (38779-0242-8) | July 16, 2015 |
| 38779-0242-9 | 38779-0242 | Medisca Inc. | 769.2 g in 1 JAR (38779-0242-9) | July 16, 2015 |
| 72603-491-01 | 72603-491 | Northstar Rx LLC | 15 g in 1 BOTTLE, PLASTIC (72603-491-01) | September 1, 2025 |
| 72603-491-02 | 72603-491 | Northstar Rx LLC | 30 g in 1 BOTTLE, PLASTIC (72603-491-02) | September 1, 2025 |
| 72603-491-03 | 72603-491 | Northstar Rx LLC | 60 g in 1 BOTTLE, PLASTIC (72603-491-03) | September 1, 2025 |
| 17337-0330-0 | 17337-0330 | Olon S.p.A. | 16.84 kg in 1 BOX (17337-0330-0) | February 15, 2024 |
| 17337-0331-0 | 17337-0331 | Olon S.p.A. | 12.15 kg in 1 BOX (17337-0331-0) | February 15, 2024 |
| 51927-0095-0 | 51927-0095 | Professional Compounding Centers of America | 1 kg in 1 BOTTLE (51927-0095-0) | May 3, 2021 |
| 53734-336-01 | 53734-336 | VUAB Pharma A.S. | 1.55 kg in 1 CONTAINER (53734-336-01) | August 10, 2017 |
| 53734-336-02 | 53734-336 | VUAB Pharma A.S. | 8 kg in 1 CONTAINER (53734-336-02) | August 10, 2017 |
| 53734-336-03 | 53734-336 | VUAB Pharma A.S. | 15.5 kg in 1 CONTAINER (53734-336-03) | August 10, 2017 |
| 70771-1585-1 | 70771-1585 | Zydus Lifesciences Limited | 15 g in 1 BOTTLE, PLASTIC (70771-1585-1) | October 6, 2021 |
| 70771-1585-2 | 70771-1585 | Zydus Lifesciences Limited | 30 g in 1 BOTTLE, PLASTIC (70771-1585-2) | October 6, 2021 |
| 70771-1585-3 | 70771-1585 | Zydus Lifesciences Limited | 60 g in 1 BOTTLE, PLASTIC (70771-1585-3) | October 6, 2021 |
| 68382-370-01 | 68382-370 | Zydus Pharmaceuticals USA Inc. | 15 g in 1 BOTTLE, PLASTIC (68382-370-01) | October 6, 2021 |
| 68382-370-02 | 68382-370 | Zydus Pharmaceuticals USA Inc. | 30 g in 1 BOTTLE, PLASTIC (68382-370-02) | October 6, 2021 |
| 68382-370-03 | 68382-370 | Zydus Pharmaceuticals USA Inc. | 60 g in 1 BOTTLE, PLASTIC (68382-370-03) | October 6, 2021 |
| 65415-1371 | 65415-1371 | Antibiotice SA | — | March 20, 2014 |
| 65415-1372 | 65415-1372 | Antibiotice SA | — | March 20, 2014 |
| 68254-2506 | 68254-2506 | Concord Biotech Limited | — | October 8, 2023 |
| 75907-060 | 75907-060 | Dr. Reddy's Labratories Inc. | — | May 28, 2024 |
| 67630-0016 | 67630-0016 | FUJIAN FUKANG PHARMACEUTICAL CO., LTD. | — | February 13, 2026 |
| 62991-2785 | 62991-2785 | LETCO MEDICAL, LLC | — | June 19, 2009 |
| 69315-306 | 69315-306 | Leading Pharma, LLC | — | April 23, 2018 |
| 38779-0242 | 38779-0242 | Medisca Inc. | — | July 16, 2015 |
| 72603-491 | 72603-491 | Northstar Rx LLC | — | September 1, 2025 |
| 17337-0330 | 17337-0330 | Olon S.p.A. | — | February 15, 2024 |
| 17337-0331 | 17337-0331 | Olon S.p.A. | — | February 15, 2024 |
| 51927-0095 | 51927-0095 | Professional Compounding Centers of America | — | May 3, 2021 |
| 53734-336 | 53734-336 | VUAB Pharma A.S. | — | August 10, 2017 |
| 70771-1585 | 70771-1585 | Zydus Lifesciences Limited | — | October 6, 2021 |
| 68382-370 | 68382-370 | Zydus Pharmaceuticals USA Inc. | — | October 6, 2021 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.